SCLX vs. NVAX, SANA, AVXL, RGNX, VALN, AGEN, ITOS, EXAI, CHRS, and ALEC
Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Novavax (NVAX), Sana Biotechnology (SANA), Anavex Life Sciences (AVXL), REGENXBIO (RGNX), Valneva (VALN), Agenus (AGEN), iTeos Therapeutics (ITOS), Exscientia (EXAI), Coherus BioSciences (CHRS), and Alector (ALEC). These companies are all part of the "biological products, except diagnostic" industry.
Scilex vs.
Novavax (NASDAQ:NVAX) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.
Novavax has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Scilex has a beta of -0.35, suggesting that its stock price is 135% less volatile than the S&P 500.
Scilex has a net margin of 0.00% compared to Novavax's net margin of -71.59%. Novavax's return on equity of 0.00% beat Scilex's return on equity.
Scilex has lower revenue, but higher earnings than Novavax.
In the previous week, Novavax had 5 more articles in the media than Scilex. MarketBeat recorded 12 mentions for Novavax and 7 mentions for Scilex. Novavax's average media sentiment score of 0.44 beat Scilex's score of 0.35 indicating that Novavax is being referred to more favorably in the media.
Novavax received 837 more outperform votes than Scilex when rated by MarketBeat users.
Novavax presently has a consensus target price of $92.50, suggesting a potential upside of 719.31%. Given Novavax's higher probable upside, equities analysts clearly believe Novavax is more favorable than Scilex.
45.7% of Novavax shares are held by institutional investors. Comparatively, 72.7% of Scilex shares are held by institutional investors. 2.1% of Novavax shares are held by company insiders. Comparatively, 20.0% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Novavax beats Scilex on 8 of the 13 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
